AI
CRNX icon

Atom Investors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Atom Investors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,887
Closed -$229K – 519
2024
Q1 		$229K Buy
+4,887
New +$191K 0.03% 468
2023
Q4 		– Sell
-17,893
Closed -$532K – 469
2023
Q3 		$532K Buy
+17,893
New +$369K 0.12% 219
2023
Q2 		– Sell
-12,886
Closed -$207K – 309
2023
Q1 		$207K Sell
12,886
-68,580
-84% -$1.27M 0.11% 205
2022
Q4 		$1.49M Buy
81,466
+32,541
+67% +$573K 0.75% 32
2022
Q3 		$961K Sell
48,925
-9,676
-17% -$197K 0.34% 94
2022
Q2 		$1.09M Buy
58,601
+7,065
+14% +$141K 0.48% 59
2022
Q1 		$1.13M Buy
51,536
+11,547
+29% +$234K 0.53% 41
2021
Q4 		$1.14M Buy
+39,989
New +$986K 0.19% 99

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Atom Investors's CRNX Position: Q2 2024 in Review

Atom Investors sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2024, closing a stake of 4,887 shares — an estimated $229K sold.

Atom Investors first reported a position in CRNX in Q4 2021 and held it in 8 quarters. The position peaked at $1.49M in Q4 2022. 234 funds tracked by Wall St. Rank hold CRNX as of Q2 2024.

  • Atom Investors reported no remaining Crinetics Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Atom Investors sold 4,887 Crinetics Pharmaceuticals shares in Q2 2024, an estimated $229K.
  • Atom Investors first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • Atom Investors's Crinetics Pharmaceuticals position peaked at $1.49M in Q4 2022.
  • 234 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2024.

Based on Atom Investors's 13F filing for Q2 2024, filed 14 Aug 2024.